Physician profile
Julio Rodriguez
NPI 1649272055
$11,789.99
in general payments reported to CMS, 2019-2025
46 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,568 · 2020: $1,563 · 2021: $2,532 · 2022: $1,863 · 2023: $1,102 · 2024: $1,273 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,264.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,029.41 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $1,497.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,020.98 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbott Laboratories | $721.08 | 2020-2025 | Proclaim |
| Lilly USA, LLC | $629.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $583.07 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $465.14 | 2019-2023 | |
| Astellas Pharma US INC | $457.47 | 2019-2025 | Veozah |
| Pfizer INC. | $453.80 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $427.32 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $422.53 | 2019-2024 | Gardasil 9, Verquvo, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.47 | 2019-2025 | Jardiance |
| Abbvie INC. | $318.48 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $291.90 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $288.82 | 2019-2023 | Xarelto |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.